Search for: "SCHERING-PLOUGH"
Results 321 - 340
of 404
Sort by Relevance
|
Sort by Date
22 Apr 2008, 5:09 pm
Specific talks of interest include the following: Strategic Considerations for the ANDA Applicant's Pre-Litigation Strategy and Initial Obligations Rethinking Paragraph IV Challenges in View of Shifting Obviousness Standards Litigating with Multiple ANDA Filers: Brand-Name and Generic Perspectives View From the Bench: Judicial Views on Paragraph IV Litigation (with three federal judges on the panel) Mitigating Antitrust Concerns When Settling a Paragraph IV Action Mastering the Interplay… [read post]
17 Apr 2008, 10:39 am
March 25, 2008) ("the Court may take judicial notice of and consider the public records of the FDA, such as the Public Health Advisory"); Schering-Plough Healthcare Products, Inc. v. [read post]
16 Apr 2008, 10:04 am
The Schering-Plough developed drug, Vytorin, is marketed in America to not only lower LDL cholesterol levels, but also to limit plaque buildup in arteries. [read post]
14 Apr 2008, 11:52 am
This marketing effort helped drug makers Merck and Schering-Plough gain a 15 percent market share for cholesterol lowing drugs in the US. [read post]
1 Apr 2008, 11:03 pm
Vytorin, developed and marketed jointly by Merck and Schering-Plough, is a combination of cholesterol-lowering Zetia and the statin Zocor. [read post]
31 Mar 2008, 4:46 am
Merck and Schering-Plough countered by saying "they believe Vytorin failed to show a... [read post]
25 Mar 2008, 8:09 am
The staff of the Corporation Finance Division has allowed Schering-Plough and JP Morgan Chase to omit a new bylaw proposal that seeks an independent lead director after rejecting requests by AT&T and Boeing to exclude the same resolution. [read post]
17 Mar 2008, 12:06 pm
Other speakers include Kathleen Fonda, Legal Advisor Office Of Patent Legal Administration, USPTO, James Gould from Schering-Plough, Robert Hrubiec, VP Intellectual Property and Chief Patent Counsel, Cephalon, Lee Caffin, DVP Global IP Strategy for Abbott Laboratories, and Luisa Bigornia, Vice President Intellectual Property, BioMarin Pharmaceutical. [read post]
8 Mar 2008, 12:14 am
Schering-Plough Healthcare Products, Inc. v. [read post]
3 Mar 2008, 3:38 pm
Accordingly, Schering-Plough – a Section 1 case — is inapposite. [read post]
22 Feb 2008, 1:30 pm
In a crushing blow to consumers, on Thursday, February 21st, the United States Supreme Court again sided with big pharmaceutical medical device makers. [read post]
19 Feb 2008, 7:09 pm
Pharmaceutical fraud recoveries included $704 million from drug manufacturer Serono, and $435 million from Schering-Plough. [read post]
15 Feb 2008, 1:49 am
The FDA has approved a change in the product labels for cholesterol drugs Vytorin and Zetia, adding depression as a possible side effect of the drug.In letters to the drugs' co-marketers, Schering-Plough Corp. [read post]
7 Feb 2008, 8:48 am
Cesan — former CEO of Schering-Plough; noted Levitra expert Daniel H. [read post]
6 Feb 2008, 3:04 pm
This press release includes a link to an an ENHANCE Chronology (PDF format) prepared by Merck and/or Schering-Plough which is seemingly intended to reinforce the claims made in their press release. [read post]
4 Feb 2008, 8:23 am
Schering-Plough Corp., No. 06-06823, 2007 WL 1839789 (N.D. [read post]
29 Jan 2008, 10:41 am
” “We have done nothing wrong and we stand behind this product,” said Rosemarie Yancosek, a spokeswoman for Schering-Plough. [read post]
28 Jan 2008, 2:15 am
Related Post: FTC Approves Mergers after Divestitures: A&P, Schering-Plough. [read post]
25 Jan 2008, 12:12 pm
Article in the Wall Street Journal -- Merck, Schering-Plough Defend Efforts for Vytorin, Zetia, by the Associated Press. [read post]
21 Jan 2008, 9:41 pm
Inc. and Schering-Plough Corp. [read post]
